Chapter 11: Mental Health Screening: Anxiety, Depression, Eating Disorders, PTSD, Substance Abuse, Suicide, and Dementia

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a medical emergency where 45 percent of the victims actually saw a doctor just one month before the tragedy and yet somehow the warning signs were entirely missed.

Right, which sounds like a massive systemic failure.

Exactly, it sounds impossible but this happens like every single day.

We're talking about suicide and those patients are sitting right there in primary care clinics.

It's just a staggering reality to confront and I think it highlights why assessing someone's mental state in a primary care setting isn't just a matter of asking, you know, Yeah, not even close.

Right, it is an incredibly complex diagnostic landscape.

You are navigating these really muddy waters where physical symptoms are often masking deep, deep psychological distress.

Which is exactly why today's deep dive is so critical.

So welcome everyone.

Today our mission is to decode chapter 11 on mental health screening from Advanced Health Assessment of Women, fifth edition.

A really dense but crucial chapter.

Oh, totally.

And whether you are a healthcare student prepping for your first clinicals, advanced practice nurse,

or just someone who's fascinated by how providers actually evaluate mental health,

we are going to translate these dense clinical protocols into practical real world knowledge for you.

Yeah, we're basically giving you the clinical flight manual today.

I love that analogy.

Like what instruments to look at when a patient is sitting in the exam room, how to interpret those dials, and what emergency procedures to initiate if things start going wrong.

And we are going to cover a lot of ground today.

I mean, we're looking at a highly systematic approach from anxiety and depression all the way to PTSD,

substance abuse, and dementia.

So a little bit of everything.

Pretty much.

The goal is to connect the dots so that your history taking naturally supports your physical exam, which then, of course, drives your clinical interpretation and your management steps.

Right.

But to start reading those clinical instruments, we first have to establish a baseline.

Like what actually is mental health?

Right.

It's a big question.

It is.

And the World Health Organization defines it as much more than just the absence of mental illness.

It is this really complex dynamic mix of biological,

environmental, and socioeconomic factors.

And the sheer volume of people who experience disruptions in that baseline is immense.

I mean, the CDC reports that over 50 % of the U .S.

population will experience at least one mental illness episode in their lifetime.

Over 50%.

That's half the country.

But, you know, when we look at this through the specific women's health lens that the chapter provides, a very distinct pattern emerges.

Oh, interesting.

Like what?

Well, women are significantly more likely than men to take mental health medication.

We're talking 20 .6 % of women compared to just 10 .7 % of men.

Wow.

That's almost double.

Yeah.

And they are also much more likely to receive therapy.

Which really makes you wonder what's driving that disparity.

I mean, is this chapter tailored to women's health because of strict biological differences, or is it more about situational stressors?

It's deeply intertwined, actually.

The textbook highlights conditions that are entirely unique to female biology and reproductive life cycles.

Like postpartum.

Exactly.

Perinatal depression.

Which, by the way, isn't just feeling overwhelmed by a newborn.

It's a massive hormonal crash combined with intense sleep deprivation.

A totally physiological event.

And then there is premenstrual dysphoric disorder, or PMDD, which is a severe sensitivity to regular hormonal fluctuations, and also perimenopause -related depression.

So there is these specific biological windows.

Yes.

But on top of those windows, generalized anxiety and depression are simply more common in women overall.

But regardless of the specific diagnosis, there is a golden rule for management established right at the beginning of the text.

A combined approach.

Yes.

The most effective treatment approaches always incorporate both therapy and medication.

You really need both.

Okay.

So let's look at the first major condition you'll encounter in clinic using that approach.

Anxiety.

It affects 19 .1 % of US adults.

Which is about 48 million people.

Just a massive number.

And women have twice the risk of generalized anxiety disorder, or GAD.

But here is the statistic that completely reframes how we should view anxiety.

90 % of those diagnosed with GAD will develop at least one other mental health disorder in their lifetime.

That 90 % comorbidity rate is wild.

And it's exactly why generalized screening is an absolute bottleneck in primary care.

You have to catch it early.

Right.

Catching that initial anxiety is essential for case finding.

You aren't just treating a patient who feels nervous.

You are trying to intercept the whole cascade of secondary conditions like depression or substance abuse that almost inevitably follow.

So how do you actually flag it in a 15 -minute visit without bogging down the entire appointment?

The text provides two main tools for this, right?

The GAD2 and the GAD7.

Yep.

Those are the gold standards.

And I look at the GAD2 as your clinical smoke detector.

It's just two fast questions asking about feeling nervous or not being able to stop worrying over the last two weeks.

Right.

It's very brief.

It doesn't tell you exactly what's burning.

It just tells you if there's smoke.

And a positive response to that triggers the GAD7.

Exactly.

And if the GAD2 is the smoke detector, the GAD7 is the fire investigator.

It's a longer five -question tool.

But what's crucial to understand here for clinical practice is the scoring threshold.

Okay.

Break that down for us.

Well, a score above eight, which actually sits right in the mid -range of what's considered mild anxiety,

acts as a hard positive screen.

Oh, so even if it's technically mild, it's a red flag.

Yes.

That specific number is your trigger to stop and perform a full, in -depth assessment using DSM -5 criteria.

You don't just look at it and say, well, it's only mild, no big deal.

You investigate.

And when it's time to manage that anxiety, the approach is stepwise.

You start with non -pharmacologic options, right?

Like cognitive behavioral therapy.

Absolutely.

And CBT isn't just talking about your feelings.

It's highly effective because it actually rewires cognitive distortions causing the anxiety.

The text says it's comparable to medication in long -term efficacy.

It really is.

But when you do move to pharmacology, specifically SSRIs, the textbook drops a massive clinical pearl about dosing.

This is a critical safety step for any prescriber.

Tell me about it.

When initiating an SSRI for anxiety, the standard recommendation is to actually start at one half of the normal starting dose.

Wait, really?

Just half?

Why is that?

Because you want to avoid what's called activation.

When you first introduce an SSRI, the serotonin levels in the brain shift before the receptors have fully adapted.

Oh, I see.

Yeah.

And this causes a transient increase in anxiety.

It's a jittery, restless feeling that basically mimics the very condition you are trying to treat.

That sounds awful for the patient.

It is, which is why starting at half dose minimizes this effect.

And you also have to aggressively educate the patient that it can take up to 12 weeks for the medication to exert its anti -anxiety effects.

12 weeks?

That feels like an eternity for a patient who is suffering right now.

Which perfectly explains why patients often push for benzodiazine.

Oh, constantly.

They want that rapid, immediate relief.

They do.

And benzos absolutely provide that immediate off switch for panic.

But the text explicitly warns that they are strictly second -line agents.

Because of the addiction risk.

Exactly.

That rapid relief is exactly what makes them so dangerous.

You are chemically reinforcing the brain's desire for an instant escape, which makes them highly, highly addictive.

And the numbers back that up aggressively.

Up to 44 % of patients who use benzodiazepines for just four to six weeks report physical withdrawal symptoms when they try to stop.

Just a few weeks and they are hooked.

Yeah.

Furthermore, for women of childbearing age, these drugs rapidly distribute into breast milk in sufficient quantities to actually produce pharmacologic effects in newborns, like lethargy and poor feeding.

That severe risk profile is why providers need to pivot to other second -line therapies if the SSRIs aren't cutting it.

Like what?

What's the alternative?

Medications like buspirone or hydroxazine.

They are slower acting.

Buspirone can take two weeks or more to build up in the system, but they don't carry that addiction potential or the severe withdrawal risks.

Okay.

That makes a lot of sense.

Now, if 90 % of those with generalized anxiety develop another disorder,

what usually happens?

Ominous depression.

Right.

Major depressive disorder affects 8 .4 % of adults.

And the risk factors are heavily concentrated in the exact populations we're discussing today.

Female gender, low income, and having a first degree relative with depression.

And the recurrence risk is incredibly heavy too.

Yeah.

50 % of patients recover after one episode.

But if you have two episodes, you face a 70 % chance of recurrence.

So to reliably catch depression, students and providers use the SIGCAPS mnemonic.

It's a total cornerstone of psychiatric history taking, but it's vital to understand why it works.

Right.

It's not just a random acronym.

No.

Notice how SIGCAPS doesn't just ask if you feel sad.

It's actively looking for the physical biological breakdown of the body.

It stands for sleep disturbance,

interest loss,

guilt,

energy loss,

concentration impairment, appetite changes,

psychomotor agitation or retardation,

and suicidal ideations.

That psychomotor piece is fascinating to me.

We're talking about a patient physically moving like a motor is running, or conversely moving slowly like they are trudging through molasses.

It's a full body illness.

It really is.

And practically, this mnemonic maps directly onto the PHQ -9 questionnaire, which is the primary nine question tool based on the DSM -5.

But before a provider writes a prescription to treat that depression, we have to talk about what I'm calling the

Oh, this, yes.

This cannot be overstated.

It is a massive safety check.

Break it down for us.

Before you treat a patient's depression with an SSRI, you must ask about a personal or family history of mania or hypomania.

Why is that so crucial?

Because if you give an SSRI to a patient with undiagnosed bipolar disorder, the medication can trigger an activation response that actually precipitates a full -blown manic episode.

Oh, wow.

Yeah.

If there is a history of mania, you do not start the depression medication.

You immediately refer them to psychiatry.

You are literally avoiding throwing gasoline on a fire.

That's incredible.

Now, for the patients who do have unipolar depression but just don't respond to standard medications, the text outlines advanced treatments.

There is transcranial magnetic stimulation or TMS, which uses magnetic fields five days a week to stimulate nerve cells.

And then there is electroconvulsive therapy or ECT.

An ECT often carries this heavy historical stigma, but the clinical reality framed in the text is quite different.

It's actually really effective, right?

Highly effective.

Up to 80 % to 90 % efficacy for severe major depressive disorder.

And more importantly for women's health, it is safe to use during pregnancy.

That's amazing.

It is.

It's a definitive treatment of choice for patients experiencing severe suicidal ideation or food refusal, where you just do not have 12 weeks to wait for an SSRI to kick in.

Treating severe depression aggressively is crucial because of the ultimate worst case scenario, which leads us back to the statistic we opened with.

Suicide.

It is a medical emergency in primary care.

There are 130 suicides per day in the U .S.

And the fact that 45 % of people who die by suicide saw their primary care provider within one month before their death.

It's just a chilling reality check.

Especially when you compare that to the fact that only 20 % of those victims saw a mental health professional in that same preceding month.

Wow.

So the PCPs are really the ones seeing them.

Exactly.

The burden of detection falls squarely on the primary care provider.

It's an immense responsibility.

You really are the first line of defense.

But I know a lot of providers, especially students, hesitate to ask about suicide directly because of this persistent myth that asking about it will somehow plant the idea in the patient's head.

And the text shatters that myth completely.

Asking a patient about suicide does not introduce the idea.

The individual has almost always been thinking about it long before you bring it up.

So it's safe to ask.

More than safe.

By asking directly, you are actually throwing them a lifeline.

You are giving them permission to talk about the absolute darkest thing in their mind.

To assess that risk systematically, we use another mnemonic, right?

Okay.

Is path warm.

That's the one.

Ideation, substance abuse, purposelessness, anxiety trapped, hopelessness, withdrawal,

anger, recklessness, and mood change.

It really paints a picture of someone who has lost all their tethers to safety and reality.

It does.

And once that clinical picture emerges, you move to structured tools like the safety five -step evaluation or the Columbia suicide severity rating scale.

Which are more than just checklists.

Right.

They are tools to explore risk factors versus protective factors, like does the patient have a plan?

Do they have the actual means to execute that plan?

Do they have children at home that act as a protective tether?

Oh, I see.

Yeah.

This stratifies the patient into low, moderate, or high -risk groups, which dictates whether they need imminent emergency psychiatric hospitalization.

We just spent a lot of time talking about how SSRIs are a frontline treatment for anxiety and depression.

But there is a specific subset of patients where prescribing an SSRI can actually backfire, causing them to abandon treatment altogether.

A really tricky demographic.

Yeah.

And that brings us to eating disorders.

These affect 9 % of adults, and they peak right around ages 19 to 20.

And that peak age makes perfect sense clinically.

Ages 19 to 20 represent a massive life transition.

You're leaving home, starting college, navigating new independence.

So it's about control.

Exactly.

When individuals feel they have lost control over their environment, controlling their food intake becomes this maladaptive coping mechanism, and it's a grueling illness.

The average duration lasts between 9 .3 and 14 .7 years.

That is heartbreaking.

To screen for this, providers rely on the ESP -5 question screen, the SGOF questionnaire, or the gold standard, the EDEQ.

All right.

Those are the main ones.

But the management section holds a crucial insight about the physical toll.

The text stresses that inpatient care becomes absolutely necessary when dangerous physical signs manifest.

We aren't just talking about being thin.

We're talking about a drop in systolic blood pressure, severe arrhythmias, or hypokalemia.

Hypokalemia is the critical one to watch for.

It's a severe drop in potassium, which means the electrical system of the heart is completely destabilized.

It can literally stop the heart.

It can.

But here is the paradox in treating eating disorders.

Psychopharmacology is often totally ineffective.

Wait, really?

Why is that?

Because many psychiatric medications, like atypical antipsychotics or certain antidepressants, cause weight gain as a side effect.

For a patient with anorexia or bulimia, gaining five pounds is completely objectionable.

They will simply stop taking the medication.

Oh, of course.

That makes total sense.

Therefore, the text emphasizes that nutritional rehabilitation and intense psychotherapy are the paramount treatments, not just throwing pills at the problem.

It makes complete sense when you understand the why behind the patient's behavior.

So let's pivot to a condition where behavior is dictated by a past event, PTSD or post -traumatic stress disorder.

Which affects 3 .6 % of adults.

Right.

And the text differentiates PTSD from a simple normal fear response by noting a specific biological failure.

The body basically fails to return to its pre -traumatic state.

The nervous system just gets stuck in overdrive.

And the gold standard screening tool here is the PC -PTSD -5.

It is incredibly efficient.

If a patient answers no to the very first question, which just asks if they have experienced a trauma, the screening stops immediately.

So you don't waste clinical time.

Right.

But if they screen positive, the first line management is trauma -focused psychotherapy coupled with an SSRI or SNRI.

Okay, hold on.

Let me stop you there.

If the defining feature of PTSD is this overwhelming fear response, panic, and an inability to calm down, why wouldn't we just use a fast -acting benzodiazepine to immediately calm their nervous system?

It seems like the logical, compassionate thing to do, right?

But absolutely not.

The text explicitly warns against benzodiazepines for PTSD.

They have zero longitudinal efficacy, meaning they do nothing to cure the condition over time.

Worse, PTSD recovery requires the patient to cognitively process the trauma.

Benzodiazepines essentially numb the brain, preventing that necessary cognitive processing.

You are chemically reinforcing the avoidance behavior, which actually accentuates the fear response and worsens their overall long -term recovery.

Wow.

So trying for a quick fix actually deeply harms their ability to heal.

That is a vital distinction for any practitioner.

Absolutely vital.

As we look at the final specific screenings in the chapter, we confront substance abuse and dementia.

For substance use disorders, or SUD,

60 .2 % of the U .S.

population use drugs, including alcohol and tobacco, in the last 30 days.

That's a huge number.

Yet despite how common it is, only 20 % of those in active treatment programs are women.

And the text highlights the intense complexity of dual diagnosis here.

That's when a patient has both a substance use disorder and a co -occurring mental health disorder, like alcohol dependence combined with severe depression.

You can't really treat one without addressing the other.

You can't.

To catch SUDs in primary care, providers rely heavily on the CAGE questionnaire for alcohol, and the CAGE aid, which includes drugs.

The CAGE acronym is brilliant because of how it bypasses a patient's natural defensiveness.

If you ask someone how much they drink, they usually have the number.

But CAGE asks,

have you ever felt you should cut down?

Have people annoyed you by criticizing your drinking?

Have you ever felt guilty about your drinking?

Have you ever needed an eye -opener drink first thing in the morning?

It targets the psychological impact and dependency, not the sheer volume.

Exactly.

It forces the provider to look at the behavioral consequences.

When it comes to management, particularly with alcohol, there is a strict, bolded safety warning in the text.

At home, detoxification from alcohol is not recommended.

Too dangerous.

Extremely.

Alcohol withdrawal can trigger severe, life -threatening seizure activity.

Detoxification requires strict medical supervision.

Good to know.

Yeah.

Once they are safely detoxed, providers can utilize medications like naltrexone, which blocks the euphoric effects of alcohol, or acamprosate and disulfiram.

And support groups play a massive role in maintaining that sobriety.

AA and NA are the most common, but the text makes a point to note that for patients who find the religious or spiritual components of those groups objectionable, there are secular alternatives too.

Like smart recovery and SOS.

Exactly.

Finally, rounding out our specific screenings, we have dementia, referred to in the DSM -5 as neurocognitive disorders.

Alzheimer's is the most common, affecting 5 .6 million adults over 65.

Right.

And assessing dementia isn't just asking if someone forgot their keys.

The alterations happen in very specific brain domains.

Complex attention, executive function, learning and memory, language, perceptual motor skills, and social cognition.

To systematically test those domains, providers use the Mini Mental State Exam, or the MMSE.

It's an 11 -question test with a maximum score of 30.

And it tests those specific domains, right?

Yes, very specifically.

Like asking a patient to spell the word world backwards tests complex attention.

Asking them to draw intersecting pentagons tests perceptual motor skills.

A score of 23 or less indicates cognitive impairment.

So you have all of these individual screening tools and physiological pearls.

But the true test of a healthcare provider is synthesizing them when a real human being is actually sitting in front of you.

Bringing it all together.

Right.

And the text provides a brilliant culminating case study to put everything we've just discussed into practice.

Well, let's walk through it.

So imagine you are the provider.

A 32 -year -old pregnant Hispanic female presents for her very first prenatal checkup.

She tells you she takes Lexapro, which is an SSRI, for anxiety and depression.

Okay.

Noting the SSRI.

She is absolutely terrified of stopping this medication because of a past severe suicide attempt via overdose.

During the family history, she mentions her mother has bipolar disorder.

Red flag there.

And then, almost as a side note on her way out, she mentions wanting to start a rigorous exercise program to avoid getting, quote, too fat while pregnant.

Wow.

Okay.

This is where you have to look at the whole clinical picture.

Let's apply what we've learned.

First, the bipolar pearl.

Her mother has bipolar disorder.

Before you, as the provider, continue or adjust her SSRI, you must assess this patient for a personal history of mania.

Right.

You cannot risk throwing her into a manic episode during her pregnancy.

Exactly.

Second, the suicide risk.

She has a past attempt via medication overdose, firmly placing her in a high -risk category.

You have to carefully weigh the risks of continuing a psychiatric medication during pregnancy against the severe, life -threatening risk of her relapsing into suicidal ideation if she stops her Lexapro.

It's a delicate balance.

It really is.

Third, you cannot ignore that passing comment about not wanting to get too fat.

That is a massive clinical clue.

It seems like a throwaway line, but it's not.

Not at all.

That should immediately trigger a sexy -off or ESP screening to ensure she isn't developing an eating disorder or risking severe malnutrition for a developing fetus.

It is entirely connected.

The history taking supports the focused examination, the examination supports your interpretation, and that drives your management.

She clearly needs a referral to her psych provider and a holistic, combined approach of therapy and carefully managed medication.

This case perfectly illustrates how a simple, routine, primary care visit can instantly uncover complex layers of psychological depth.

It really does.

And it shows why these structured tools, the GD -7, the PHQ -9, the IS Pathworm Pneumonic, the CAGE Questionnaire, they aren't just academic exercises to memorize for a board exam.

They are literal lifesavers.

100%.

For you listening, mastering these steps is about catching that 45 % of suicidal patients who are sitting right there in an exam room just a month before a tragedy.

Which leaves us with a much larger systemic issue to ponder, honestly.

We've just spent this deep dive discussing a dozen highly specific screening tools, complex medication interactions, and deep psychological histories.

But in our modern healthcare system, a primary care visit lasts an average of just 15 minutes.

And that is the ultimate challenge.

How do we redesign our clinics, our intake processes, and our own clinical workflows so that providers actually have the time to listen to the answers these life -saving tools provide?

Exactly.

Having the clinical flight manual is totally useless if you don't have the time to read the instrument before the plane goes down.

Thank you so much for joining us on this deep dive from all of us here on the show and the Last Minute Lecture Team.

Keep questioning the systems and keep learning the underlying why.

And next time you're looking at a patient's chart, remember you're not just looking for the broken bones of the simple answers.

You're looking at an incredibly complex human being.

Catch you next time.